累积限定日剂量可客观评估IgG4相关病治疗强度并预测结局
研究发现丙氨酸氨基转移酶升高、血清IgG较高和类固醇暴露较高(>1225 cDDD)独立预测复发,贫血(Hb <10.9 g/dl)预测复发和死亡。增殖型和纤维化型亚型具有不同风险和治疗反应,cDDD评估支持分期精准管理。
要点
- ALT升高、IgG较高和类固醇暴露>1225 cDDD独立预测复发
- 贫血(Hb <10.9 g/dl)预测复发和死亡
- 纤维化型年龄较大、肾功能受损、复发风险较低
核心结论
- 增殖型和纤维化型IgG4相关病具有不同风险和治疗反应,cDDD可客观评估治疗强度并预测结局。
主要发现
- 硫唑嘌呤cDDD和羟氯喹cDDD与ALT水平呈弱正相关。
- ALT升高、血清IgG较高和类固醇暴露>1225 cDDD独立预测复发。
- 贫血(Hb <10.9 g/dl)预测复发和死亡。
- IgG较低(<1600 mg/dl)、类固醇暴露较低(<1225 cDDD)或分类为无应答者较少发生 flare。
- 纤维化型与年龄较大、肾功能受损和较低复发风险相关,但较高羟氯喹剂量和贫血增加复发风险。
关键数值与推荐
- 类固醇暴露>1225 cDDD独立预测复发,<1225 cDDD较少发生 flare。
- Hb <10.9 g/dl预测复发和死亡。
- IgG <1600 mg/dl较少发生 flare。
临床怎么用
- 可用cDDD量化糖皮质激素和免疫抑制剂累积暴露,辅助评估治疗强度和预测复发风险。
- 对ALT升高、IgG较高、类固醇暴露>1225 cDDD或贫血(Hb <10.9 g/dl)者应加强复发监测。
- 纤维化型患者需关注肾功能和贫血,增殖型患者对免疫抑制治疗反应较好但首次复发中位时间较短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Immunoglobulin G4-related disease (IgG4-RD) is a chronic fibroinflammatory disorder with heterogeneous clinical behaviour. Although glucocorticoids remain the mainstay of treatment, relapse and fibrosis are common. This study investigated predictors of relapse and mortality, integrating disease subtype and cumulative drug exposure using the defined daily dose (DDD) framework. METHODS: Eighty-five patients fulfilling the 2020 revised comprehensive diagnostic criteria for IgG4-RD were retrospectively analysed. Clinical features, laboratory data and cumulative DDD (cDDD) of corticosteroids and immunosuppressants were compared between proliferative or fibrotic subtypes. Multivariate Cox regression identified predictors of relapse and mortality, and forest plots were used for overall and subgroup analysis. RESULTS: Azathioprine cDDD and hydroxychloroquine cDDD showed a weak positive correlation with alanine aminotransferase (ALT) levels, which reflects hepatic involvement of IgG4-RD. Elevated ALT, higher serum IgG and greater steroid exposure (>1225 cDDD) independently predicted relapse, while anaemia (Hb <10.9 g/dl) predicted both relapse and mortality. Lower IgG levels (<1600 mg/dl), low steroid exposure (<1225 cDDD), or classified as non-responders were less likely to experience flare. Early hydroxychloroquine use and lower initial steroid exposure were linked to improved survival. The fibrotic subtype was associated with older age, renal impairment, and lower flare risk, but higher hydroxychloroquine dosage and anaemia increased risk of flare. Proliferative disease exhibited greater responsiveness to immunosuppressive therapy but has shorter median time to first relapse. CONCLUSION: Distinct proliferative and fibrotic phenotypes exhibit divergent risks and treatment responses. Quantitative cDDD assessment enables objective evaluation of therapeutic intensity and outcome prediction, supporting a stage-tailored, precision approach to IgG4-RD management.
引用
- Tsai HC, Lu HY, Tsai CY, et al. Cumulative defined daily doses enable objective assessment of treatment intensity and outcome prediction in immunoglobulin G4-related disease and its subtypes. Rheumatology (Oxford). 2026. PMID: 41883149. doi:10.1093/rheumatology/keag133
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。